David Young - Feb 6, 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Pres. Research & Development, Director
Signature
/s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Feb 6, 2024
Transactions value $
$50,504
Form type
4
Date filed
2/7/2024, 04:22 PM
Previous filing
Apr 12, 2024
Next filing
Feb 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Purchase $50.5K +20K +52.1% $2.53 58.4K Feb 6, 2024 Direct F1
holding PCSA Common Stock 31K Feb 6, 2024 By Young-Plaisance Revocable Trust F1
holding PCSA Common Stock 10.8K Feb 6, 2024 By Family Entities F1
holding PCSA Common Stock 18.5K Feb 6, 2024 By CorLyst, LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.